Article

Lithium Placental Passage and Obstetrical Outcome: Implications for Clinical Management During Late Pregnancy

Harvard University, Cambridge, Massachusetts, United States
American Journal of Psychiatry (Impact Factor: 13.56). 12/2005; 162(11):2162-70. DOI: 10.1176/appi.ajp.162.11.2162
Source: PubMed

ABSTRACT Lithium has been used during pregnancy for more than four decades, but quantification of fetal lithium exposure and clinical correlations of such exposure are limited. The study objectives were to 1) quantify the rate of lithium placental passage, 2) assess any association between plasma concentration of lithium at delivery and adverse perinatal events, and 3) determine whether lithium concentrations can be reduced by briefly suspending therapy proximate to delivery.
Maternal blood and umbilical cord blood were obtained at delivery for assay of lithium concentrations, and obstetrical outcome data were collected prospectively for 10 participants. These data were combined with results from MEDLINE and PsycINFO searches that identified 32 cases in which maternal lithium was administered throughout delivery. Statistical analysis of the pooled data was conducted.
The ratio of lithium concentrations in umbilical cord blood to maternal blood (mean=1.05, SD=0.13) was uniform across a wide range of maternal concentrations (0.2-2.6 meq/liter). Significantly lower Apgar scores, longer hospital stays, and higher rates of CNS and neuromuscular complications were observed in infants with higher lithium concentrations (>0.64 meq/liter) at delivery. Withholding lithium therapy for 24-48 hours before delivery resulted in a 0.28 meq/liter reduction in maternal lithium concentration.
Lithium completely equilibrates across the placenta. Higher lithium concentrations at delivery are associated with more perinatal complications, and lithium concentrations can be reduced by brief suspension of therapy proximate to delivery. Treatment guidelines are proposed to improve neonatal well-being when lithium use is indicated in late pregnancy.

Download full-text

Full-text

Available from: D Jeffrey Newport, Aug 28, 2015
0 Followers
 · 
138 Views
  • Source
    • "In terms of fetal exposure to these drugs, the total concentration of VPA has been shown to be higher in cord serum than in the serum of epileptic mothers prescribed this drug [13], [14]. In comparison, lithium appears to equilibriate across the placenta over a range of maternal concentrations [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mood stabilising drugs such as lithium (LiCl) and valproic acid (VPA) are the first line agents for treating conditions such as Bipolar disorder and Epilepsy. However, these drugs have potential developmental effects that are not fully understood. This study explores the use of a simple human neurosphere-based in vitro model to characterise the pharmacological and toxicological effects of LiCl and VPA using gene expression changes linked to phenotypic alterations in cells. Treatment with VPA and LiCl resulted in the differential expression of 331 and 164 genes respectively. In the subset of VPA targeted genes, 114 were downregulated whilst 217 genes were upregulated. In the subset of LiCl targeted genes, 73 were downregulated and 91 were upregulated. Gene ontology (GO) term enrichment analysis was used to highlight the most relevant GO terms associated with a given gene list following toxin exposure. In addition, in order to phenotypically anchor the gene expression data, changes in the heterogeneity of cell subtype populations and cell cycle phase were monitored using flow cytometry. Whilst LiCl exposure did not significantly alter the proportion of cells expressing markers for stem cells/undifferentiated cells (Oct4, SSEA4), neurons (Neurofilament M), astrocytes (GFAP) or cell cycle phase, the drug caused a 1.4-fold increase in total cell number. In contrast, exposure to VPA resulted in significant upregulation of Oct4, SSEA, Neurofilament M and GFAP with significant decreases in both G2/M phase cells and cell number. This neurosphere model might provide the basis of a human-based cellular approach for the regulatory exploration of developmental impact of potential toxic chemicals.
    PLoS ONE 03/2013; 8(3):e58822. DOI:10.1371/journal.pone.0058822 · 3.23 Impact Factor
  • Source
    • "Such drugs include lithium chloride and lithium salts, which are known to activate the Wnt pathway through inhibition of GSK3 [84]. Underscoring the relative safety record of lithium salts, they are used to treat bipolar disorder not only in adulthood but during older childhood and adolescence [85], and even during pregnancy, with limited risk to the fetus despite equilibration across the placenta [86, 87]. Lithium chloride was also studied in adult patients with low-grade neuroendocrine tumors (NET), as GSK3β regulates growth and hormone production in NETs; however, it was ineffective at inhibiting NET growth [88]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence, accounting for approximately 7% of childhood cancers. Current therapies include nonspecific cytotoxic chemotherapy regimens, radiation therapy, and surgery; however, these multimodality strategies are unsuccessful in the majority of patients with high-risk disease. It is generally believed that these tumors represent arrested or aberrant skeletal muscle development, and, accordingly, developmental signaling pathways critical to myogenesis such as Notch, WNT, and Hedgehog may represent new therapeutic targets. In this paper, we summarize the current preclinical studies linking these embryonic pathways to rhabdomyosarcoma tumorigenesis and provide support for the investigation of targeted therapies in this embryonic cancer.
    Sarcoma 04/2012; 2012:406239. DOI:10.1155/2012/406239
  • Source
    • "Reduce maternal lithium dose to preconception amount immediately after delivery (Newport et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to provide data to aid decision making regarding lithium use during lactation. Three women treated with lithium for bipolar disorder during pregnancy and lactation and their four infants provided lithium levels at 1 month postpartum. Infant levels ranged from 10% to 17% of maternal levels. Two infants experienced early feeding problems which were overcome with breastfeeding education and support. Women taking lithium can be supported to breastfeed, and their infants should be followed closely until breastfeeding is well established.
    Archives of Women s Mental Health 02/2012; 15(1):69-72. DOI:10.1007/s00737-012-0257-3 · 1.96 Impact Factor
Show more